Decoy Therapeutics Inc.
DCOY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001615219
No open-market purchases or sales by Decoy Therapeutics Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $31.0K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 4
- 13F valueReported value at the end of Q2 2026
- $31.0K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding DCOY, Q2 2026
No superinvestor reported holding DCOY at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Decoy Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 2, 2026 (view filing) | Dec 30, 2025 | 3 days | Hanish Arnold CDirector | SSale | −15 | $0.64 | −$9.6 | −0.3%5.00K after | |
| Jan 2, 2026 (view filing) | Dec 30, 2025 | 3 days | Hanish Arnold CDirector | SSale | −12 | $0.64 | −$7.68 | −100.0%0 after | |
| Nov 24, 2025 (view filing) | Nov 20 | 4 days | Hanish Arnold CDirector | PPurchase | +5.00K | $0.75 | +$3.75K | +33,333.3%5.01K after | |
| Nov 20, 2025 (view filing) | Nov 20 | Same day | Rosenblum Mark JExec VP Finance, CFO | PPurchase | +20.0K | $0.80 | +$16.0K | +11,299.4%20.2K after | |
| Jun 8, 2022 (view filing)3:14 PM ET | Jun 7 | 1 day | Burleson TessDirector | PPurchase | +27.7K | $0.18 | +$4.99K | +636.8%32.0K after | |
| Jun 8, 2022 (view filing)3:12 PM ET | Jun 7 | 1 day | Lieber Jonathan IDirector | PPurchase | +37.5K | $0.1871 | +$7.02K | New position37.5K after | |
| Jun 7, 2022 (view filing)4:33 PM ET | Jun 6 | 1 day | McVicar William K.Director | PPurchase | +26.6K | $0.1883 | +$5.00K | New position26.6K after | |
| Jun 6, 2022 (view filing)8:33 PM ET | Jun 3 | 3 days | Hanish Arnold CDirector | PPurchase | +28.0K | $0.184 | +$5.15K | +152.6%46.4K after | |
| Jun 6, 2022 (view filing) | Aug 21, 2020 | 654 days | Hanish Arnold CDirector | PPurchase | +4.00K | $0.98 | +$3.92K | +54.4%11.3K after | Amended |
| Jun 6, 2022 (view filing) | Feb 11, 2020 | 846 days | Hanish Arnold CDirector | PPurchase | +4.35K | $1.15 | +$5.00K | +145.0%7.35K after | Amended |
Top 10 13F holders, Q2 2026
The largest institutional positions in Decoy Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 4,034 | $29.0K | 0.00% | +4,034 | New |
| Tower Research Capital LLC (TRC) | 256 | $1.84K | 0.00% | −765−74.9% | Reduced |
| UBS Group AG | 25 | $180 | 0.00% | −521−95.4% | Reduced |
| Caitong International Asset Management Co., Ltd | 2 | $14 | 0.00% | +2 | New |